

China Cord Blood, Cordlife join hands for stem cell therapy services

25 July 2014 | News | By BioSpectrum Bureau



Singapore: China Cord Blood Corporation (CCBC) and Cordlife Group, a multi-product healthcare company catering to the mother and child segment, have come together to assist patients across China, Singapore, Hong Kong, Indonesia, India, Philippines and Malaysia to identify suitable cord blood matching units for stem cell therapy.

Under the Memorandum of Understanding signed between the two companies, Cordlife, on behalf of its patients who are in need of cord blood stem cell therapy, can facilitate the process by providing relevant information to CCBC, who will then perform searches for possible matching units among its donated cord blood samples in China. For patients who reside in China, CCBC may seek Cordlife's assistance or contacts to source possible cord blood unit matches in the relevant public cord blood registries in the regions where Cordlife operates, which include Hong Kong, Singapore, India, Indonesia, the Philippines, and Malaysia.

Mr KAM Yuen, chairman, China Cord Blood Corporation commented, "Both CCBC and Cordlife share a common vision which is to enhance people's lives through the widening of umbilical cord blood stem cells application services. Our proposed collaboration will assist families in China and other parts of Asia who face difficulties obtaining a matching cord blood unit to widen their search, resulting in the increased likelihood of receiving treatment."

Mr Jeremy Yee, executive director and chief executive officer of Cordlife said, "We are glad to collaborate with CCBC in a joint effort to make cord blood stem cell therapy more widely available to our patients, particularly those who have difficulty finding a matching cord blood unit. Our two companies share a common goal of providing the best services, saving lives and improving quality of life for people in the Asia region."